PTPN13 and malignant colon neoplasm: Thus, Ac-SLV competes with FasR for the binding to FAP-1 (Yanagisawa et al, 1997; Sawa et al, 1999), prominently enhancing FasR sensitivity of colon cancer cells in the FasR-refractory group.